摘要
目的:促进骨科术后患者非甾体抗炎药(NSAID)的合理使用,保证患者用药安全。方法:利用处方前置审核,建立NSAID精准化审核数据库,开展前置审核干预,并回顾性对2020年1—6月(干预前)、2021年1—6月(干预后)该院骨折术后患者NSAID使用情况进行人工点评,比较干预前后不合理用药情况、疼痛评分及药品不良反应发生率的差异。结果:干预后,NSAID不合理使用率由干预前的31.61%(141/446)明显降至8.17%(41/502),差异有统计学意义(P<0.05);注射剂超疗程、联合用药不适宜等问题发生率较干预前明显降低,差异均有统计学意义(P<0.01);药品不良反应发生率从干预前的2.69%(12/446)明显降至0.80%(4/502),差异有统计学意义(P<0.05)。干预前后,患者术后镇痛效果相当。结论:处方前置审核数据库的建立和应用,可有效规范术后NSAID的合理应用,保证患者用药安全,促进药学服务发展。
OBJECTIVE:To promote the rational application of nonsteroidal anti-inflammatory drug(NSAID)in patients after orthopedic surgery,so as to ensure medication safety.METHODS:Using prescription pre-review to build NSAID precise vetting database and conduct pre-review intervention,and a manual review on the application of NSAID in patients after fracture surgery in this hospital from Jan.to Jun.2020(before intervention)and from Jan.to Jun.2021(after intervention)was retrospectively conducted,so that the differences in irrational medication,pain scores and incidences of adverse drug reactions before and after the intervention were compared.RESULTS:After intervention,the irrational usage rate of NSAID had significantly decreased from 31.61%(141/446)before intervention to 8.17%(41/502),with statistically significant difference(P<0.05);the incidences of problems such as over-treatment of injections and inappropriate drug combination had significantly decreased compared with that of before intervention,with statistically significant difference(P<0.01);the incidence of adverse drug reactions had decreased from 2.69%(12/446)before intervention to 0.80%(4/502),with statistically significant difference(P<0.05).The postoperative analgesic effects of the patients were comparable before and after intervention.CONCLUSIONS:The establishment and application of prescription pre-review database can effectively regulate the rational application of NSAID after surgery,ensure medication safety and promote the development of pharmacy services.
作者
王璐
吴丽欣
任红
张红煜
耿志辉
WANG Lu;WU Lixin;REN Hong;ZHANG Hongyu;GENG Zhihui(Dept.of Pharmacy,Baoding No.1 Central Hospital,Hebei Baoding 071000,China)
出处
《中国医院用药评价与分析》
2022年第1期118-121,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
河北省医学科学研究课题计划项目(No.20191238)。
关键词
处方前置审核
非甾体抗炎药
合理用药
药品不良反应
Prescription pre-review
Nonsteroidal anti-inflammatory drug
Rational medication
Adverse drug reaction
作者简介
王璐,主管药师。研究方向:临床药学。E-mail:381817259@qq.com;通信作者:耿志辉,主任药师。研究方向:医院药学。E-mail:gengzhihui666@sohu.com。
